Since 2001, APS has demonstrated its commitment to preventing RSV in premature babies
Synagis®
Our local, agile presence gives us a patient-centered advantage. APS is committed to delivering superior Clinical and Personalized Specialty Care.
Since 2001, APS has demonstrated its commitment to preventing RSV in premature babies
Our local, agile presence gives us a patient-centered advantage. APS is committed to delivering superior Clinical and Personalized Specialty Care.
APS provides most state-of-the-art self-injectable drug therapies
Since 2001, APS has demonstrated its commitment to preventing Respiratory Syncytial Virus (RSV) in premature babies and other at-risk children. We have proven our commitment by becoming the largest, single provider of Synagis® (Palivizimub) to the California Medi-Cal based programs. With consistently exceeding a 97% compliance rate, APS remains one of the top Synagis® providers in the United States. APS has also successfully expanded its Synagis® program into Idaho, Colorado, Washington, Wyoming, Montana and Alaska whereby patients, physicians and caregivers receive the same excellent care and outcomes.
Our Synagis® Management System (SMS™) is unique versus our competitors. Our diligent tracking and monitoring of patients receiving Synagis® is unsurpassed. This includes looking closely at patients who marginally did not qualify to receive the mono-clonal antibody and looking for additional documentation and opinion that may otherwise qualify the patient.
For Synagis® Referral Coordinators, APS makes it easy to refer a baby by providing forms that can be downloaded, edited or written and securely submitted.